As per the American Cancer Society, it is estimated that 19,950 new cases of acute myeloid leukemia (AML) are expected, in 2016; most of the cases are in adults. Due to AML, nearly 10,430 deaths are expected in 2016 in the United States itself. The National Cancer Institute states that only 26.6% diagnosed cases survive for five years. New drug launches and targeted therapy trends are propelling the growth of the market. The increasing access to drugs in the emerging economies, due to these countriesâ€™ government initiatives, and increasing spending on the development of healthcare facilities in these regions are fueling the growth of the market.
Key factors propelling the growth of the market, globally, are -
High incidence and prevalence rate of acute myeloid leukemia
Increasing expenditure on healthcare
Increasing investments in R&D
Advancement in pharmacology and molecular biology, promoting drug development
The key factors turning out to be constraints for this market are -
Complications due to chemotherapy
Stringent regulatory guidelines
The market has been segmented based on chemotherapeutics and geography. The chemotherapeutics segment includes cytarabine, anthracycline drugs, alkylating agents, anti-metabolites, tyrosine kinase inhibitors, hormonal therapy and others. The anthracycline drugs have been further segmented into Daunomycin, Idarubicin, and Mitoxantrone. The tyrosine kinase inhibitors include Dasatinib and Imatinib.
Geographically, the market has been segmented into North America, Europe, Asia-Pacific, the Middle East & Africa and South America.
The key players in this market are
This Report Offers:
Market definition, along with identification of key drivers and restraints for the market.
Market analysis with region-specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.
Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.
A comprehensive list of key market players, along with the analysis of their current strategic interests and key financial information.
An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain critical insight into the factors driving and restraining the market, in addition to opportunities, offered.
1.1 Study Deliverables
1.2 Market Definition
1.3 General Study Assumptions
1.4 Report Descritption
2. Research Methodology
3. Executive Summary
4. Market Overview and Industry Trends
4.1 Current Market Scenario
4.2 Porter's Five Forces
4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Consumers
4.2.3 Threat of New Entrants
4.2.4 Threat of Substitute Products and Services
4.2.5 Competitive Rivalry Within the Industry
5. Market Drivers, Restraints, Opportunities and Challenges
5.1 Market Drivers
5.1.1 High Incidence and Prevalence of Acute Myeloid Leukemia
5.1.2 Increasing Investments In R&D
5.1.3 Advancement in Pharmacology & Molecular Biology to Promote Drug Development
5.2 Market Restraints
5.2.1 Stringent Regulations on Drugs
5.2.2 Complications Related to Chemotherapy
5.3 Market Opportunities
5.4 Market Challenges
6. Market Segmentation
6.1 By Chemotherapy
6.1.2 Anthracycline Drugs
6.1.3 Alkylating Agents
6.1.5 Tyrosine Kinase Inhibitors
18.104.22.168 Dasatinib (Sprycel)
22.214.171.124 Imatinib (Gleevec)
6.1.6 Hormonal Therapy
7. Market Segmentation by Geography
7.1 North America
7.2.3 United Kingdom
7.2.6 Rest of Europe
7.3.4 South Korea
7.3.5 Australia & New Zealand
7.3.6 Rest of Asia-Pacific
7.4 The Middle East & North Africa
7.4.2 South Africa
7.4.3 Rest of MENA
7.5 South America
7.5.3 Rest of South America
8. Competitive Landscape
8.1 New Product Launches
8.2 Mergers and Acqisitions
8.3 Agreement, Collaboration and Partnerships
9. Company Profiles
9.1 Celegene Corporation
9.2 Novartis AG
9.3 Clavis Pharma
9.4 Eisai Co. Ltd.
9.5 Genzyme Corporation
9.6 Cephalon Inc.
9.7 Ambit bioscience corporation
9.8 Bristol Myer Squibb
10. Future Outlook of the Market